Sugi Predict

Sugi Predict / Compounds / SCHEMBL11775855

SCHEMBL11775855

SCHEMBL11775855

Cc1nc(Cl)nc(N)c1Br

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.52
▸ IDO1 P14902 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ NR1I2 O75469 1/20 0.37
▸ AHR P35869 1/20 0.37
▸ CDK1 P06493 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ TLR8 Q9NR97 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30696400 1.00 LMNA (0.52) LMNAIDO1HTTNR1I2AHR
SCHEMBL4597901 0.84 LMNA (0.42) LMNAIDO1NR1I2AHRALDH1A1
SCHEMBL4068928 0.77 LMNA (0.37) LMNANR1I2AHRALDH1A1ALOX15
SCHEMBL19984155 0.77 PDE10A (0.38) LMNAIDO1HTTCDK1ALDH1A1
SCHEMBL19754271 0.77 IDO1 (0.41) LMNAIDO1HTTCDK1ALDH1A1
SCHEMBL6474069 0.77 CDK1 (0.35) LMNAIDO1HTTCDK1ALDH1A1
SCHEMBL29350081 0.77 LMNA (0.37) LMNANR1I2AHRALDH1A1ALOX15
SCHEMBL30696398 0.74 KMT2A (0.42) LMNAHTTCDK1ALDH1A1ALOX15
SCHEMBL13851094 0.74 LMNA (0.56) LMNAIDO1NR1I2AHRALDH1A1
SCHEMBL2551248 0.74 KMT2A (0.42) LMNAHTTCDK1ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547336-A1 USP1 INHIBITORS AND USES THEREOF Zentaur Therapeutics USA Inc. (US) 2025-05-07 — — EP disclosed
US-12281118-B2 Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2025-04-22 — — US disclosed
CN-119836421-A USP1 inhibitors and uses thereof 森韬医药美国公司 2025-04-15 — — CN disclosed
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2024-05-16 — — US disclosed
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. 2024-03-28 — — US disclosed
US-20240092779-A1 USP1 INHIBITORS AND USES THEREOF ZENTAUR THERAPEUTICS USA INC. 2024-03-21 — — US disclosed
CN-111433205-B Polycyclic compounds as allosteric SHP2 inhibitors 锐新医药公司 2024-01-19 — — CN disclosed
WO-2024006879-A1 USP1 INHIBITORS AND USES THEREOF ZENTAUR THERAPEUTICS USA INC. (US) 2024-01-04 — — WO disclosed
EP-3724189-B1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS REVOLUTION MEDICINES INC (US) 2023-10-04 — — EP disclosed
EP-3724189-B1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS REVOLUTION MEDICINES INC (US) 2023-10-04 — — EP disclosed
EP-3878853-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE Shanghai Ringene BioPharma Co., Ltd. (CN) 2021-09-15 — — EP disclosed
EP-3878853-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE Shanghai Ringene BioPharma Co., Ltd. (CN) 2021-09-15 — — EP disclosed
US-20200407372-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. 2020-12-31 — — US disclosed
CN-112020500-A Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase 拉文纳制药公司 2020-12-01 — — CN disclosed
EP-3728228-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 — — EP disclosed
EP-3724189-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2020-10-21 — — EP disclosed
CN-111433205-A Polycyclic compounds as allosteric SHP2 inhibitors 锐新医药公司 2020-07-17 — — CN disclosed
CN-111153901-A Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application 如东凌达生物医药科技有限公司 2020-05-15 — — CN disclosed
WO-2019118909-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2019-06-20 — — WO disclosed
US-3932408-A PESTICIDES, HERBICIDES, FUNGICIDES WACKER-CHEMIE GMBH (DT) 1976-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281118-B2 Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use PTPN1, PTPN7, PTPN9 LMNA 4854/4885IDO1 905/4885HTT 2746/4885
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1B, PIP5K1A, PIP5K1C LMNA 4267/4885IDO1 1777/4885HTT 2194/4885
US-20240092779-A1 USP1 INHIBITORS AND USES THEREOF USP1, USP28, USP2 LMNA 2542/4885IDO1 1584/4885HTT 955/4885
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS PTPN18, PTPN1, PTPRJ LMNA 4870/4885IDO1 2300/4885HTT 943/4885
US-20200407372-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS PTPN18, PTPN1, PTPRJ LMNA 4870/4885IDO1 2300/4885HTT 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.